SecBot SecBot
6-K ·Filed Jul 22, 2026

GSK

GSK plc
BULLISH
Impact 6/10
Horizonweeks Processed3mo ago SEC0001654954-26-006789
Notable filing: 6-K
Actionable Insight ▲ Bullish

Monitor Jideytro launch trajectory and prescription data over next 2-3 quarters to gauge market penetration. The next major pipeline catalyst is the neladalkib PDUFA on November 27, 2026, which could further derisk the Nuvalent acquisition thesis. Ris-Rez phase III data in small-cell lung cancer from Hansoh Pharma also warrants attention.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

GSK drug pipeline →

Neladalkib

▲ Bullish Named in this 6-K
Impact
Phase
Filed/PDUFA (NDA under FDA Priority Review)
Time to market
If approved, US launch would follow the November 27, 2026 PDUFA date (~3 months away); approval is not guaranteed.
Next catalyst
None dated

What to watchFor GSK shareholders the near-term binary is November 27, 2026: FDA decision on neladalkib (with sibling ROS1 drug zidesamtinib's PDUFA on September 18, 2026 as a read-through). Note the direct equity upside of this drug was already captured, Nuvalent (NUVL) shareholders were cashed out at $124.00/share on July 15, 2026, so any remaining exposure is through mega-cap GSK, where one oncology NDA moves the stock by low single-digit percentages. Watch for FDA advisory-committee activity and any confirmatory-trial requirements before the PDUFA.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$50.76
T+0 close · Jul 22, 2026 · via day close
Latest settled
−3.43%
T+60 · $49.02
Vs SPY
−6.69%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 22 $50.76entry
  2. T+1 · 4mo ago −0.04%α +1.20% · $50.74
  3. T+5 · 4mo ago +4.85%α +7.25% · $53.22
  4. T+20 · 3mo ago +4.18%α +1.28% · $52.88
  5. T+60 · 5w ago −3.43%α −6.69% · $49.02
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

GSK announced FDA approval of Jideytro (zidesamtinib) for previously treated ROS1-positive non-small cell lung cancer, ahead of the original PDUFA date of September 18, 2026. This is GSK's first approved lung cancer therapy and the first product from the recently completed Nuvalent acquisition, validating the deal's strategic rationale. The approval is based on the ARROS-1 phase I/II trial (ORR 44%, 12-month DOR rate 69%) and adds a targeted option for an oncogenic driver with ~50,000 annual diagnoses worldwide.

Key Facts

  • FDA approved Jideytro (zidesamtinib) for ROS1-positive locally advanced or metastatic NSCLC after prior ROS1 TKI
  • Approval granted ahead of original target action date (Sept 18, 2026) under Breakthrough Therapy and Orphan Drug designations
  • ARROS-1 trial showed ORR 44% (95% CI 34-53%) in pre-treated population (n=117); 12-month DOR rate 69%
  • Jideytro is GSK's first lung cancer approval and first asset from the recently completed Nuvalent acquisition
  • Additional Nuvalent pipeline assets: neladalkib (NVL-655) for ALK-altered NSCLC under FDA review (PDUFA Nov 27, 2026); NVL-330 for HER2-altered NSCLC
  • Positive phase III data for risvutatug rezetecan (Ris-Rez) in relapsed small-cell lung cancer recently reported by licensor Hansoh Pharma

Financial Impact

Near-term revenue contribution likely modest for a $103B company given ROS1+ NSCLC represents ~1-2% of lung cancer cases; strategic value is higher as it validates the Nuvalent acquisition and expands GSK's oncology pipeline into lung cancer.

revenuepipeline value

Risk Factors

  • Competition from established ROS1 inhibitors (entrectinib, repotrectinib) with earlier-line approvals
  • Pricing and reimbursement headwinds in a concentrated targeted therapy market
  • Adverse event profile (edema, peripheral neuropathy, fatigue) may limit adoption vs. better-tolerated alternatives
  • Launch execution risk given GSK's limited prior experience in lung cancer commercialisation

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
43% bullish (30 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-006789
Document: 0001654954-26-006789-index-headers.html0001654954-26-006789
Document: 0001654954-26-006789-index.html0001654954-26-006789
Document: 0001654954-26-006789.txt0001654954-26-006789

US Market Status

Market Closed · Opens Wed (10h 25m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 22, 2026